Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Journal of Neuro-Oncology|July 14, 2016
Age alone is not a predictor for survival in glioblastomaLucy Gately, Anna Collins, Michael Murphy, et al.Journal of Neuro-Oncology|October 29, 2017
Long-term survivors of glioblastoma: a closer lookLucy Gately, Sue-Anne McLachlan, Jennifer Philip, et al.CNS Oncology|February 8, 2019
A feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma in AustraliaMichael Murphy, Anthony Dowling, Christopher Thien, et al.Journal of Neuro-Oncology|July 2, 2014
Living longer with adult high-grade glioma: setting a research agenda for patients and their caregiversBethany Russell, Anna Collins, Michael Dally, et al.Endocrinology, Diabetes & Metabolism Case Reports|March 11, 2015
Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumourSally K Abell, Jessie Teng, Anthony Dowling, et al.Frontiers in Oncology|March 14, 2015
Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticityLinda M McInnes, Natalie Jacobson, Andrew Redfern, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|December 17, 2005
Phase II study of two-weekly temozolomide in patients with high-grade gliomasShirley Wong, Mark A Rosenthal, Anthony Dowling, et al.Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|August 5, 2011
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapySumitra Ananda, Anna K Nowak, Lawrence Cher, et al.Neuro-Oncology|February 11, 2004
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiformeSusan L Chua, Mark A Rosenthal, Shirley S Wong, et al.Neuro-Oncology|April 22, 2010
A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumorsHui K Gan, Mark A Rosenthal, Anthony Dowling, et al.Pageof 2